Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01242371 · ClinicalTrials.gov registry record · NA
Double-Blind Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia
A NA study of Schizophrenia and Schizoaffective Disorder, sponsored by Sheppard Pratt Health System.
- Completed
- Registry status
- NA
- Development phase
- 65
- Enrollment target
- 1
- Study location
NCT01242371 is a NA study of Schizophrenia and Schizoaffective Disorder that has completed, run by Sheppard Pratt Health System. The registered enrollment target is 65 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01242371, a NA study of Schizophrenia and Schizoaffective Disorder, has completed, sponsored by Sheppard Pratt Health System.
- COMPLETED
- Registry status
- NA
- Development phase
- 65 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators intend to explore the hypothesis that symptoms of schizophrenia may be reduced by the administration of a probiotic supplement when used in addition to standard antipsychotic medications.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Probiotic Supplement
- DIETARY_SUPPLEMENT Identical-appearing Placebo
Study Locations (1)
Maryland
- Sheppart Pratt Health System - Towson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2010-08 |
| Est. Completion | 2012-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01242371
The ClinicalTrials.gov registry entry for NCT01242371 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (70% lower). The listed sponsor is Sheppard Pratt Health System, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Probiotic Supplement is the first listed.
NCT01242371 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01242371 about?
NCT01242371 is a clinical study titled "Double-Blind Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia". The investigators intend to explore the hypothesis that symptoms of schizophrenia may be reduced by the administration of a probiotic supplement when used in addition to standard antipsychotic medications.
What is the current status of trial NCT01242371?
This trial is currently completed. It is a NA study. The enrollment target is 65 participants. The study started on 2010-08. Estimated completion is 2012-08.
What conditions does trial NCT01242371 study?
This clinical trial studies the following conditions: Schizophrenia, Schizoaffective Disorder.
What interventions are being tested in trial NCT01242371?
The interventions under investigation include: Probiotic Supplement (DIETARY_SUPPLEMENT), Identical-appearing Placebo (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01242371?
This trial is sponsored by Sheppard Pratt Health System, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01242371 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Taking Action for College Students
RECRUITING · NA
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
RECRUITING · NA
-
Cerebellar Modulation of Cognition in Psychosis
RECRUITING · NA
-
TMS for Inhibition Enhancement in Schizophrenia
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.